Compare VVPR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVPR | CTSO |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 45.9M |
| IPO Year | 2016 | N/A |
| Metric | VVPR | CTSO |
|---|---|---|
| Price | $3.20 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | ★ 498.2K | 114.9K |
| Earning Date | 09-02-2023 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $61,000.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 281.25 | 23.89 |
| 52 Week Low | $0.62 | $0.60 |
| 52 Week High | $8.88 | $1.61 |
| Indicator | VVPR | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 40.33 |
| Support Level | $2.59 | $0.60 |
| Resistance Level | $3.20 | $0.76 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 91.38 | 16.74 |
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.